Europe has an energy crisis. Factories are halting operations in the face of soaring energy prices; families are paying 50% more for heating (or opting to freeze in their homes), and Europe as a whole continues to destabilize its political position by making itself more dependent on Russia for natural gas.
Almost every patient who gets myeloma and is treated with a standard therapy also experiences relapse. But researchers have developed an antibody therapy that triggers the immune system to destroy these cancer cells. The bispecific antibody can bind to T cells and multiple myeloma cells at once, to kill the cancer. This immunotherapy, called talquetamab, was astonishingly effective, and worked in about 73 percent of patients who were treated with the drug in two clinical trials. The treatment even helped for a patient who had a cancer that resisted all therapies that have been approved for multiple myeloma.
Talquetamab takes advantage of a receptor on myeloma cells called GPRC5D, and CD3, a complex and co-receptor on the surface of T cells. Anti-CD3 antibodies have long been known to cause the activation of T cells. Mouse studies showed that talquetamab can recruit and activate CD3-positive T-cells, which inhibits the formation and growth of tumors.
The explanation of inertia based on “Mach’s principle” is briefly revisited and an experiment whereby the gravitational origin of inertia can be tested is described. The test consists of detecting a small stationary force with a sensitive force sensor. The force is presumably induced when a periodic transient Mach effect mass fluctuation is driven in high voltage, high energy density capacitors that are subjected to 50 kHz, 1.3 kV amplitude voltage signal, and threaded by an alternating magnetic flux of the same frequency. An effect of the sort predicted is shown to be present in the device tested. It has the expected magnitude and depends on the relative phase of the Mach effect mass fluctuation and the alternating magnetic flux as expected. The observed effect also displays scaling behaviors that are unique to Mach effects.
The Food and Drug Administration (FDA) considers aging to be a natural process. This makes it difficult to get FDA approval for drugs that seek to slow or reverse the biological process of aging. Instead, drugs intended to target aging must target a disease that often results from the aging process in order to demonstrate efficacy and gain approval.
But there is growing consensus and effort among scientists to convince the FDA that aging itself should be classified as a disease and an appropriate target for drug development.
Dr. Bruce Lipton, PhD Explains how cells work, and how important cell voltage, vibration, and frequency is…
Speaker: Bruce Lipton PhD https://www.brucelipton.com.
Bruce is the author of “The Biology of Belief” https://amzn.to/2IG4CsL
This is the — dark, cold — time of year when hibernating memes start flying around social media. ‘Wake me up in spring!’ being a classic example. It’s natural for humans to sleep a bit more in winter. Reduced light exposure tells the body to produce melatonin, a hormone that makes us sleepier.
What is your cough trying to tell you? Our expert, family medicine specialist Alex Gusler, M.D., weighs in.
A small enterprising team of filmmakers used ChatGPT to write and direct a short movie augmented by other AI programs.
A new information-stealing malware named ‘RisePro’ is being distributed through fake cracks sites operated by the PrivateLoader pay-per-install (PPI) malware distribution service.
RisePro is designed to help attackers steal victims’ credit cards, passwords, and crypto wallets from infected devices.
The malware was spotted by analysts at Flashpoint and Sekoia this week, with both cybersecurity firms confirming that RisePro is a previously undocumented information stealer now being distributed via fake software cracks and key generators.
